Want to see AU:EIQ full AI Analyst Report?
Top Page
EchoIQ Limited
(Sydney:EIQ)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.53
â–¼(-61.93% Downside)
Action:Reiterated
Date:09/22/26
The score is driven primarily by very weak financial performance (widening losses and persistent cash burn), partially offset by low leverage. Technicals add additional pressure due to a clear downtrend (price below key moving averages and negative MACD), while valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Minimal Financial Leverage
Minimal financial leverage reduces the company’s exposure to interest costs, refinancing pressure, and debt covenant constraints. This gives EchoIQ greater flexibility to allocate available funds toward product development and operations, although it does not eliminate the need to address ongoing cash consumption.
Negative Factors
Deepening Operating Losses
Widening losses despite the company’s technology focus indicate that revenue has not yet reached a scale capable of covering its cost structure. Continued negative margins weaken internal funding capacity, increase dependence on financing, and make it harder to demonstrate durable operating leverage over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal Financial Leverage
Minimal financial leverage reduces the company’s exposure to interest costs, refinancing pressure, and debt covenant constraints. This gives EchoIQ greater flexibility to allocate available funds toward product development and operations, although it does not eliminate the need to address ongoing cash consumption.
Read all positive factors
EchoIQ Limited (EIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$411.19M
Dividend YieldN/A
Average Volume (3M)9.74M
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue Growth-9.28%
EPS Growth-25.66%
CountryAU
Employees220
SectorHealthcare
Sector Strength45
IndustryOther Precious Metals
Share Statistics
EPS (TTM)-0.03
Shares Outstanding740,874,760
10 Day Avg. Volume3,993,804
30 Day Avg. Volume9,743,976
Financial Highlights & Ratios
PEG Ratio-2.18
Price to Book (P/B)89.24
Price to Sales (P/S)11280.71
P/FCF Ratio-97.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.91Price Target Upside-34.82% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$1.76M
EchoIQ Limited Business Overview & Revenue Model
Company Description
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, ...
EchoIQ Limited Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 92.00K | 101.41K | 44.50K | 107.33K | 251.10K |
| Gross Profit | -16.31M | -3.14M | -2.88M | -7.01M | -3.19M |
| EBITDA | -19.30M | -12.55M | -4.81M | -7.66M | -5.85M |
| Net Income | -18.57M | -13.26M | -5.41M | -8.27M | -5.99M |
Balance Sheet | |||||
| Total Assets | 13.88M | 23.37M | 8.26M | 10.38M | 10.23M |
| Cash, Cash Equivalents and Short-Term Investments | 8.71M | 6.62M | 2.12M | 3.28M | 2.41M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.25M | 615.41K | 1.49M | 3.00M | 2.21M |
| Stockholders Equity | 11.63M | 22.76M | 6.77M | 7.38M | 8.02M |
Cash Flow | |||||
| Free Cash Flow | -10.62M | -6.54M | -3.92M | -5.28M | -2.95M |
| Operating Cash Flow | -10.56M | -6.51M | -3.92M | -4.94M | -2.58M |
| Investing Cash Flow | 11.46M | -11.55M | 0.00 | -59.81K | -367.33K |
| Financing Cash Flow | 1.22M | 22.56M | 2.77M | 5.88M | 1.55M |
EchoIQ Limited Technical Analysis
Negative
1.40
Price Trends
1.05
Negative
1.22
Negative
0.97
Negative
Market Momentum
-0.13
Negative
36.55
Neutral
22.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EIQ, the sentiment is Negative. The current price of 1.4 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 1.05, and above the 200-day MA of 0.97, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 36.55 is Neutral, neither overbought nor oversold. The STOCH value of 22.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EIQ.
EchoIQ Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$2.05B | 22.57 | 29.67% | ― | ― | ― | |
46 Neutral | AU$806.37M | -8.57 | -52.04% | ― | ― | ― | |
44 Neutral | AU$1.56B | 272.73 | 5.65% | ― | 150.47% | ― | |
42 Neutral | AU$411.19M | -17.37 | -128.49% | ― | -9.28% | -25.66% | |
42 Neutral | AU$844.02M | -7.46 | -67.95% | ― | ― | -57.92% | |
42 Neutral | AU$655.77M | -2.62 | -7.06% | ― | -33.21% | -21.79% |
* Healthcare Sector Average
AU:EIQ
EchoIQ Limited
0.51
0.33
183.33%
AU:EQR
EQ Resources Limited
0.29
0.24
517.02%
AU:MI6
Minerals 260 Limited
0.84
0.48
133.33%
AU:IPX
Iperionx Limited
2.13
-6.07
-74.02%
AU:VUL
Vulcan Energy Resources Ltd.
1.20
-4.59
-79.27%
AU:BRE
Brazilian Rare Earths Ltd.
2.58
-2.73
-51.41%
EchoIQ Limited Corporate Events
Echo IQ Escalates FDA Appeal Over EchoSolv HF 510(k) Ruling
Oct 11, 2026
Echo IQ has lodged a request for supervisory review with the U.S. Food and Drug Administration after the regulator deemed its EchoSolv HF device Not Substantially Equivalent under the 510(k) process. The appeal has been accepted, and the FDA ombud...
Echo IQ sets 2026 AGM date and deadline for director nominations
Oct 6, 2026
Echo IQ has scheduled its Annual General Meeting for 24 November 2026, with full details on agenda, participation options and proxy arrangements to be provided to shareholders via a forthcoming notice and ASX announcement. The company also set 13 ...
Echo IQ Charts Path to FDA Clearance for EchoSolv HF After NSE Ruling
Sep 16, 2026
Echo IQ has outlined its strategy to secure U.S. FDA 510(k) clearance for its EchoSolv HF heart failure decision-support product after receiving a Not Substantially Equivalent determination. The company says the issues raised relate to statistical...
EchoIQ Issues 2 Million Unlisted Options in Capital Management Move
Sep 14, 2026
EchoIQ Limited has notified the market of the issue of 2 million unlisted options exercisable at $1.24 and expiring on September 1, 2029. The options form part of a previously announced transaction structure and will not be quoted on the Australia...
EchoIQ Seeks ASX Quotation for Additional 150,000 Shares
Sep 10, 2026
EchoIQ Limited has applied for quotation of an additional 150,000 ordinary fully paid shares on the ASX, with the new securities issued on 9 September 2026. The modest increase in quoted capital reflects routine capital management activity, with l...
Echo IQ schedules investor webinar to outline regulatory progress and outlook
Sep 8, 2026
Echo IQ Limited will host an investor webinar on 9 September, featuring CEO Dustin Haines, U.S. president Nick Lubbers and CFO Matthew Dodds, to brief shareholders on recent regulatory developments. Management will also outline key recent mileston...
Echo IQ faces FDA setback on EchoSolv HF but leans on strong cash and approved platform
Sep 8, 2026
Echo IQ has received a Not Substantially Equivalent determination from the U.S. Food and Drug Administration on its initial 510(k) application for EchoSolv HF, delaying clearance for commercial use of its heart failure identification technology. T...
EchoIQ Shares Halted Pending Key EchoSolv HF Regulatory Update
Sep 7, 2026
EchoIQ Limited has requested and received a trading halt on its ordinary securities from the ASX, effective 7 September 2026, pending a material announcement regarding the regulatory pathway for its EchoSolv HF product. The halt will remain in pla...
EchoIQ Reports Lapse of 500,000 Employee Options
Sep 4, 2026
EchoIQ Limited has reported the cessation of 500,000 employee options, identified as EIQAAU, following the lapse of conditional rights after the specified performance or vesting conditions were not met or became incapable of being satisfied. The o...
EchoIQ Added to S&P/ASX 300 in September Index Rebalance
Sep 4, 2026
SP Dow Jones Indices has announced a series of changes to the SP/ASX equity benchmarks, effective prior to the market open on 21 September 2026, following its quarterly review of Australian constituents. The SP/ASX 20 will remain unchanged, while ...
EchoIQ Plans Issue of 2 Million Unlisted Options
Sep 1, 2026
EchoIQ Limited has lodged a new Appendix 3B with the ASX outlining a proposed issue of up to 2,000,000 unlisted options. These options will be exercisable at $1.24 and will expire three years from the date of issue, with the proposed issue date st...
EchoIQ appoints new director with equity-linked incentive package
Sep 1, 2026
EchoIQ Limited has appointed Mr Scott Wilkin as a director effective 1 September 2026, strengthening its leadership team in the specialised field of cardiac decision-support technology. The appointment includes a letter of engagement and a grant o...
Echo IQ strengthens board with veteran healthcare investor to drive U.S. growth
Aug 31, 2026
Echo IQ has appointed veteran global healthcare investor Scott Wilkin as a Non-Executive Director, effective 1 September 2026, as it accelerates commercialisation of its EchoSolv cardiac technology suite in the U.S. and abroad. Wilkin brings 35 ye...
EchoIQ Lodges 2026 Corporate Governance Statement and ASX Appendix 4G
Aug 28, 2026
EchoIQ Limited has lodged its annual corporate governance statement for the year ended 30 June 2026 via its investor website, confirming that the document is current as of 28 August 2026 and approved by the board. The accompanying Appendix 4G outl...
Echo IQ Releases 2026 Financial Statements and Annual Report
Aug 28, 2026
Echo IQ Limited has released its financial statements for the year ended 30 June 2026, alongside its annual report and corporate directory, reaffirming its operational focus and governance structure. The publication of these documents provides sta...
Echo IQ Loss Widens as Revenue Falls and Asset Base Shrinks
Aug 28, 2026
Echo IQ Limited operates in the healthcare technology sector, focusing on diagnostic and analytical solutions that leverage advanced data and imaging capabilities for cardiac care. The company targets clinical users and healthcare providers seekin...
Echo IQ Issues New Shares Following Option Exercise
Aug 21, 2026
Echo IQ Limited has issued 100,000 fully paid ordinary shares following the exercise of unlisted options priced at $0.25 and expiring on 14 June 2027, with the new shares forming part of its existing ASX-quoted class of securities. The company sta...
EchoIQ Seeks ASX Quotation for 100,000 New Ordinary Shares
Aug 21, 2026
EchoIQ Limited has applied for the quotation of an additional 100,000 ordinary fully paid shares on the ASX, with an issue date of August 21, 2026. The move modestly increases the company’s free float and tradable share base, signalling incr...
Echo IQ Issues 1.3 Million New Shares Through Option Exercises
Aug 7, 2026
Echo IQ Limited has issued 1,300,000 fully paid ordinary shares following the exercise of unlisted options, with the new shares forming part of its existing class of securities quoted on the ASX. The company states that the issuance was conducted ...
Echo IQ issues 1.5m shares on option exercise, affirms compliance
Jul 22, 2026
Echo IQ has issued 1,500,000 fully paid ordinary shares following the exercise of unlisted options priced at $0.35 and expiring on 20 June 2028. The new shares form part of the company’s existing class of securities quoted on the Australian ...
EchoIQ Expands ASX-Listed Capital With New Share Quotation
Jul 22, 2026
EchoIQ Limited has applied for quotation on the ASX of 1,500,000 new ordinary fully paid shares under the code EIQ, issued on July 22, 2026. The move expands the company’s listed capital base and may enhance liquidity for shareholders, refle...
EchoIQ Issues 4 Million Unquoted Employee Options Under Incentive Scheme
Jul 15, 2026
EchoIQ Limited, listed on the ASX under code EIQ, utilises an employee incentive scheme that includes issuing unquoted options as part of staff compensation. These instruments are not intended to be quoted on the exchange, indicating they are prim...
Echo IQ issues 1.1m new shares via option exercise
Jul 15, 2026
Echo IQ has issued 1,100,000 fully paid ordinary shares following the exercise of unlisted options priced at $0.35, with the new shares forming part of its existing class of securities quoted on the ASX. The company confirmed that the issuance was...
EchoIQ Seeks ASX Quotation for Additional Ordinary Shares
Jul 15, 2026
EchoIQ Limited has applied for quotation on the ASX of an additional 1.1 million ordinary fully paid shares. The new securities, issued on July 10 and July 15, 2026, expand the company’s listed share capital and follow the exercise or conver...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.